Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

Just 7% of HFrEF patients received quadruple therapy, and even in this group, the absolute risk of events at 1 year was high.

Dr. Butler answers the question: 'What Is An ACE Inhibitor?' — -- Question: What is an ACE inhibitor, how does it work, and when is it used to treat heart failure? Answer: ACE inhibitors are very ...

Physician-scientists announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction. The therapy benefited patients by ...

Ryan Haumschild, PharmD, MS, MBA: Dr Anderson, I’d like to start with you. We’ve talked about guideline recommendations. Can you briefly discuss some of the real-world differences in the treatment ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Physician-scientists at The Texas Heart Institute announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction. The therapy ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

August 12, 2011 — Older patients are more likely than younger patients with a similar low left ventricular ejection fraction to have cognitive decline, report researchers. "Cognitive dysfunction due ...